Wall Street brokerages forecast that Theravance Biopharma (NASDAQ:TBPH) will post $5.74 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $9.12 million and the lowest estimate coming in at $3.50 million. Theravance Biopharma reported sales of $3.09 million in the same quarter last year, which indicates a positive year-over-year growth rate of 85.8%. The business is expected to announce its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $50.26 million for the current financial year, with estimates ranging from $40.00 million to $67.90 million. For the next financial year, analysts anticipate that the business will report sales of $90.20 million per share, with estimates ranging from $64.91 million to $105.70 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.49). The business had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $3.71 million. Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%.
Large investors have recently modified their holdings of the business. Woodford Investment Management Ltd lifted its holdings in Theravance Biopharma by 0.4% during the fourth quarter. Woodford Investment Management Ltd now owns 10,747,108 shares of the biopharmaceutical company’s stock valued at $227,270,000 after purchasing an additional 41,000 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $974,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $416,000. Schwab Charles Investment Management Inc. lifted its holdings in Theravance Biopharma by 4.2% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock valued at $5,569,000 after purchasing an additional 8,119 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $313,000. 85.98% of the stock is currently owned by institutional investors and hedge funds.
Shares of TBPH traded up $0.49 on Wednesday, reaching $22.55. The company’s stock had a trading volume of 256,656 shares, compared to its average volume of 242,950. The company has a current ratio of 6.05, a quick ratio of 5.79 and a debt-to-equity ratio of 1.94. The company has a market cap of $1,208.83, a price-to-earnings ratio of -4.14 and a beta of 1.81. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $43.44.
COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma (TBPH) Expected to Announce Quarterly Sales of $5.74 Million” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/04/23/theravance-biopharma-tbph-expected-to-announce-quarterly-sales-of-5-74-million.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.